{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+and%2For+Refractory+Multiple+Myeloma+%28RRMM%29&page=2", "query": { "condition": "Relapsed and/or Refractory Multiple Myeloma (RRMM)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+and%2For+Refractory+Multiple+Myeloma+%28RRMM%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T05:47:30.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05552976", "title": "A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 606, "start_date": "2023-01-10", "completion_date": "2029-07-25", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 34, "location_summary": "Mobile, Alabama • Cerritos, California • Irvine, California + 29 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05552976" }, { "nct_id": "NCT05519085", "title": "A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "mezigdomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 810, "start_date": "2022-09-20", "completion_date": "2033-11-30", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 56, "location_summary": "Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05519085" }, { "nct_id": "NCT06876142", "title": "Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Relapsed and/or Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 54, "start_date": "2026-06-15", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06876142" }, { "nct_id": "NCT04398745", "title": "A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-10-09", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 11, "location_summary": "Tucson, Arizona • Beverly Hills, California • Sacramento, California + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398745" }, { "nct_id": "NCT05217082", "title": "A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [], "intervention_types": [], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 35, "start_date": "2022-02-22", "completion_date": "2022-08-03", "has_results": false, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 1, "location_summary": "Morrisville, North Carolina", "locations": [ { "city": "Morrisville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05217082" }, { "nct_id": "NCT06356571", "title": "A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma Refractory" ], "interventions": [ { "name": "Isatuximab SC-OBDS", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2025-03-17", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06356571" }, { "nct_id": "NCT04000282", "title": "First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "SAR442085", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-08-19", "completion_date": "2023-09-04", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • Rochester, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04000282" }, { "nct_id": "NCT05405166", "title": "SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma Recurrent" ], "interventions": [ { "name": "Isatuximab IV", "type": "DRUG" }, { "name": "Isatuximab SC", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Paracetamol / Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 531, "start_date": "2022-06-23", "completion_date": "2027-03-23", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 23, "location_summary": "Bullhead City, Arizona • Prescott Valley, Arizona • Aurora, Colorado + 19 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405166" }, { "nct_id": "NCT07116616", "title": "A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "mRNA-2808", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2025-09-30", "completion_date": "2032-06-17", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07116616" }, { "nct_id": "NCT06171685", "title": "MMRC Horizon One: RRMM (MMRC-099)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab Monotherapy", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Multiple Myeloma Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 300, "start_date": "2024-11-17", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-11T05:47:30.886Z", "location_count": 13, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171685" } ] }